Trimethobenzamide
Tigan (trimethobenzamide) is a small molecule pharmaceutical. Trimethobenzamide was first approved as Tigan on 1982-01-01. It is used to treat nausea and vomiting in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Tigan (generic drugs available since 2003-08-20)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trimethobenzamide hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TIGAN | Par Pharmaceutical | N-017530 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tigan | New Drug Application | 2023-03-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| nausea | HP_0002018 | D009325 | R11.0 |
| vomiting | HP_0002013 | D014839 | R11.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg |
| Q0173 | Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | — | — | — | 1 | 5 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | — | — | 2 |
| Pure autonomic failure | D054970 | 1 | — | — | — | 1 | 2 | ||
| Essential hypertension | D000075222 | I10 | 1 | — | — | — | — | 1 | |
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | — | 1 | |
| Shy-drager syndrome | D012791 | EFO_1001050 | 1 | — | — | — | — | 1 | |
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | 1 | — | — | — | — | 1 | |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | 1 | — | — | — | — | 1 |
| Orthostatic intolerance | D054971 | 1 | — | — | — | — | 1 | ||
| Orthostatic hypotension | D007024 | I95.1 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIMETHOBENZAMIDE |
| INN | trimethobenzamide |
| Description | Trimethobenzamide is the amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans. It has a role as an antiemetic. It is a tertiary amino compound and a member of benzamides. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC |
Identifiers
| PDB | — |
| CAS-ID | 138-56-7 |
| RxCUI | 38685 |
| ChEMBL ID | CHEMBL1201256 |
| ChEBI ID | 27796 |
| PubChem CID | 5577 |
| DrugBank | DB00662 |
| UNII ID | W2X096QY97 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 273 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more